Haemaprot is indicated for prophylactic use to reduce preoperative blood loss and the need for blood transfusion in patients undergoing CardioPulmonary Bypass (CPB) in the course of coronary artery bypass graft surgery.

The effects of Aprotinin use in CPB involve a reduction in systemic inflammatory response, which translates into a decreased need for allogeneic blood transfusions, reduced bleeding, and decreased mediastinal reexploration for bleeding.